Compass Therapeutics Reports First Quarter Financial Results

Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 in patients with advanced biliary tract cancers . Top line data is expected in the first half of 2024Continue to enroll in a U.S.... | May 4, 2023

Related Keywords

Massachusetts , United States , Japan , Boston , Kansai , Japan General , New York , America , Danna Gifford , Richard Lindahl , Vered Bisker Leib , Thomasj Schuetz , Eli Lilly , Merck Co Inc , Merck Sharp Dohme , Development Pipeline , Compass Therapeutics Inc , University Of Virginia , Globenewswire Inc , Nasdaq , Dartmouth College , Sprint Nextel Corporation , Audit Committee , Kansai Medical University , World Medical Innovation Forum Bank , Head Of Clinical Development , Senior Vice President , Emergent Biosolutions , Chief Executive , Chief Operating , Pipeline Update , Adaptive Simon Two Stage , Chief Development Officer , Vice President , Medical University , Executive Vice President , Chief Financial Officer , Nextel Corporation , Medical Innovation Forum , Communications Manager , Compass Therapeutics , Nc Stock Exchange , News , Nformation , Ress Release , Nitiated , Patient , Enrollment , N , Hase , Study , F , Patients , Ith , Dvanced , Miliary , Tract , Cancers , Op , Line , Data , S , Xpected , He , Irst , Calf , 024continue , O , Unenroll , N Cmpx Us20454b1044 ,